Fludarabine is the most active agent in the treatment of chronic lymphocytic leukemia (CLL). Despite this activity only a minority of patients treated with fludarabine achieve a complete response. We evaluated a new treatment program of sequential therapy with fludarabine followed by high-dose cyclophosphamide in previously untreated patients with CLL. This report details the results in 25 patients with previously untreated CLL. Patients received fludarabine (25 mg/m 2 /day ؋ 5 days every 4 weeks for six cycles) as induction followed by consolidation with high-dose cyclophosphamide at one of three dose levels 1.5 g/m 2 , 2.25 g/m 2 , or 3 g/m 2 administered every 2 weeks for three doses. High-dose cyclophosphamide was given with G-CSF support (5 g/kg/day days 3-12). Complete response (CR) required a normal physical examination, normal CBC, a normal bone marrow evaluation including no residual lymphoid nodules on biopsy. A nodular response was defined as a complete response with the exception of an occasional residual nodule seen on bone marrow biopsy. Flow cytometric analysis for CD5:CD19 dual staining and / clonal excess was performed in all patients as a sensitive measure of minimal residual disease (MRD). Selected patients had patient/tumor-specific oligonucleotides generated that were subsequently used in a polymerase chain reaction as an extremely sensitive measure of MRD. There were no treatment-related deaths and no patient encountered unacceptable toxicity. After completion of this sequential regimen 76% (95% confidence interval: 59-93%) of patients had a major response: eight (32%) achieved a CR, four (16%) a nodular response, seven (28%) a PR, and six patients (24%) failed. Four patients withdrew from study during induction with fludarabine and did not receive at least one cycle of cyclophosphamide. Of the 21 patients who received consolidation with cyclophosphamide 10 (48%) had an improved quality of response when compared to that achieved with fludarabine. Two patients (8%) had no disease detectable by flow cytometry ('flow cytometric' CR) after six cycles of fludarabine. This improved to nine patients (36%) after high-dose cyclophosphamide. Following consolidation with high-dose cyclophosphamide three patients (12%) tested negative by PCR. All of these patients had morphologic evidence of residual disease after six cycles of fludarabine. Consolidation with high-dose cyclophosphamide increased the fraction of patients achieving a nodular response or CR three-fold (16% to 48%). This appears to be clinically relevant because with a median follow-up of 52 (range 34-78) months the projected 6-year survival for patients achieving a CR or NR is 91% compared to 41% for all others (P = 0.012). We conclude that sequential therapy with fludarabine followed by high-dose cyclophosphamide in previously untreated patients with CLL is safe and can improve the quality of response in a large proportion of patients compared to therapy with fludarabine alone. Leukemia (2000) 14, 1577-1582.
Introduction
Therapy for CLL has, traditionally, been palliative in intent. Conventional therapy with oral alkylating agents with or without corticosteroids produces partial responses in most patients but rarely induces complete responses. 1, 2 In general, these responses are not durable and patients ultimately succumb to progressive resistant disease. The introduction of three new agents; fludarabine, 3, 4 cladribine 5, 6 and pentostatin 7, 8 has renewed interest in aggressive therapy of selected patients with CLL. Of these drugs, fludarabine has been the most widely studied.
The ability of fludarabine to induce complete responses in a minority of previously untreated patients 9, 10 led to investigation of combination chemotherapy with corticosteroids 11, 12 or chlorambucil. 13, 14 In general, results of concomitant therapy with fludarabine combined with a second agent were disappointing with increased toxicity limiting dose intensity and without clear-cut improvement in frequency of response.
In order to take advantage of the activity of fludarabine without sacrificing dose intensity, we initiated a trial of sequential therapy in which patients received six cycles of fludarabine as induction therapy followed by three cycles of high-dose cyclophosphamide as consolidation. We hypothesized that such a regimen using these two active agents at full doses could induce a high quality sustained response that would result in the patient not requiring further chemotherapy for a prolonged period. This report details the results of treatment in previously untreated patients treated on this sequential treatment protocol.
Patients and methods

Patients
Twenty-five previously untreated patients with CLL were enrolled on this study between August 1992 and April 1996. All patients treated had active disease as defined by the NCI Working Group. 15 Patients with low risk or 'smoldering' CLL, as defined by Montserrat et al, 16 were excluded. All patients gave written informed consent.
Trial design
Patients received induction therapy with fludarabine 25 mg/m 2 /day for 5 consecutive days, given every 4 weeks for three or six cycles. After three cycles of fludarabine, patients who did not respond went on to immediately receive consolidation with high-dose cyclophosphamide. Responding patients continued fludarabine to complete six cycles prior to receiving consolidation with high-dose cyclophosphamide.
Four to six weeks after completing induction therapy with fludarabine, patients received consolidation with high-dose cyclophosphamide administered every 2-3 weeks for three cycles. If a patient developed neutropenia (Ͻ1000/l) after receiving fludarabine, they were given G-CSF (5 g/kg/day) during the period of expected neutropenia after subsequent cycles of fludarabine. In addition, all patients received G-CSF, 5 g/kg/day, starting 48 h after each cycle of high-dose cyclophosphamide for 8 days to limit neutropenia. This trial was designed to assess the practicality of administering this sequential treatment program to patients with CLL and to obtain an estimate of the response rate and the likelihood that consolidation with high-dose cyclophosphamide could improve the quality of response obtained with fludarabine. In order to ensure patient safety, the first three patients received cyclophosphamide 1.5 g/m 2 ϫ 3 cycles and the next three patients received cyclophosphamide 2.25 g/m 2 ϫ 3 cycles. The remaining patients received the target dose of cyclophosphamide 3.0 g/m 2 x 3 cycles after no unexpected toxicities were seen at the initial two dose levels.
An absolute neutrophil count (ANC) Ͼ1500/l and a platelet count Ͼ100 000/l were required prior to each chemotherapy cycle in patients with normal pre-treatment counts. Patients who began treatment with an ANC Ͻ1500/l or platelet count Ͻ100 000/l were required to have recovered these counts to at least 75% of the pre-treatment value. All patients were required to have a platelet count у50 000/l prior to each cycle of chemotherapy. Treatment was delayed if necessary for hematopoietic recovery and then administered at full dose.
Evaluation criteria
The diagnosis of CLL was established by physical examination, examination of the blood and bone marrow including flow cytometric evaluation of the malignant lymphocytes. A lymphocytosis in blood (Ͼ5000/l) and bone marrow (Ͼ30% nucleated cells) was required. (Two patients with high-risk disease treated on study had a peripheral lymphocyte count of Ͻ5000/l but had bone marrow lymphocytosis (Ͼ95%) and the typical immunophenotype of CLL). All patients had a monoclonal B lymphocyte population demonstrated by expression on the cell surface of a single immunoglobulin light chain along with expression of CD19 and/or CD20. ALL patients were required to have co-expression of CD5 with CD19 or CD20. Pre-treatment samples were used to construct patient/tumor-specific oligonucleotides for subsequent polymerase chain reaction (PCR) analysis for residual disease.
In order to assess response patients had a complete physical examination, complete blood count, bone marrow aspirate and biopsy. In addition, peripheral blood and bone marrow samples were analyzed by flow cytometry for CD5/CD19 (or CD5/CD20) dual staining and / clonal excess. Blood and bone marrow samples were also analyzed by PCR using patient/tumor-specific oligonucleotides. These evaluations were performed following three and six cycles of fludarabine, and again after completion of cyclophosphamide therapy.
A complete response (CR) required a normal physical examination; a peripheral blood lymphocyte count Ͻ4000/l, neutrophils у1500/l, untransfused hemoglobin Ͼ11 g/dl, platelets Ͼ100 000/l, a normal bone marrow aspirate with no areas of diffuse or focal increase in lymphocytes and a lymphocyte count of Ͻ30% of total nucleated cells; and a normal bone marrow biopsy without residual lymphoid nodules. A nodular PR met the criteria for CR except for residual lymphoid nodules of 'uncertain' significance seen on bone marrow biopsy as the sole abnormality.
A partial response (PR) was defined as at least a 50% reduction in size of enlarged lymph nodes, spleen and liver, along with at least a 50% decrease in peripheral blood lymphocyte count. In addition, patients achieving a PR were required to have an absolute neutrophil count у1500/l or a 50% improvement over baseline, a platelet count Ͼ100 000/l or 50% more than baseline, or an untransfused hemoglobin of at least 11 g/dl or 50% improvement over baseline. Progression of disease was defined as appearance of new lymphadenopathy or hepatosplenomegaly, or a Ͼ50% increase in lymph node, liver or spleen size. Also, a Ͼ50% increase in peripheral blood lymphocyte count constituted progression of disease. Patients who fit none of the above response categories were considered to have stable disease. Patients with either stable or progressing disease constituted treatment failures.
Following completion of therapy (until documented relapse) patients were typically followed at 2 to 3 month intervals with bone marrow examinations performed at 6 month intervals. Response duration was measured from the time of maximal response to relapse. Time to treatment failure was measured from the start of protocol therapy to the first non-protocol therapy (or death) and survival was measured from the start of protocol treatment.
Flow cytometric analysis was evaluated separately as an indication of residual disease but not included in the definition of response. A patient was considered to have no flow cytometric evidence of disease ('flow cytometric CR') if immunophenotypic analysis of peripheral blood and BM revealed a normal / ratio (no clonal excess) and a normal number of CD5/CD19 (or CD5/CD20) dual staining cells (Ͻ5% of the lymphocyte gate).
Using pre-treatment samples obtained from blood and/or bone marrow patient (tumor)-specific oligonucleotides were generated for the subsequent detection of minimal residual disease. The clone specific complementarity determining region III (CDR-III), was amplified by polymerase chain reaction (PCR) and sequenced. Based on the clone-specific sequence, nested oligonucleotide primers were constructed for each patient (tumor). These primers were then used in a two-step semi-nested 'clonotypic' PCR reaction to test subsequent blood and bone marrow samples for minimal residual disease. Semi-quantitative PCR was performed using an endpoint dilutional approach. A 'molecular' CR was defined as patients who had no evidence of disease by PCR. A more thorough review of the PCR technique used in this study is described elsewhere. 17 
Toxicity
Hematologic toxicity was graded according to the NCI working group guidelines. 15 A 0-10% decrease from baseline in platelet count or hemoglobin was grade 0. An 11-24% decline was grade 1, 25-49% grade 2, 50-74% grade 3 and a Ͼ75% decrease was grade 4. A platelet count Ͻ20 000 regardless of initial value represented grade 4 toxicity. Non-hematologic toxicity was assessed according to the NCI Common Toxicity Criteria. 18 
Statistical analysis
Response duration, time to treatment failure, and survival were calculated according to the method of Kaplan-Meier. Comparison between curves was calculated with the logrank method.
Results
Patient characteristics
Of the 25 evaluable patients 12 patients (48%) had Rai intermediate-risk disease and 13 patients (52%) had high-risk disease. Patient characteristics at entry, including gender, age, blood counts, ␤-2 microglobulin, and pattern of bone marrow involvement are detailed in Table 1 .
Response
Nineteen of the 25 patients (76%) obtained a response. Eight patients (32%) achieved a CR. Four patients (16%) were nodular PRs, seven were PRs (28%) and six patients (24%) were treatment failures. The trial was designed to assess the safety and activity of consolidation therapy with high-dose cyclophosphamide administered following induction with fludarabine. Four patients, however, withdrew from protocol therapy prior to receiving consolidation treatment with cyclophosphamide. One patient withdrew because of painful lymphadenopathy following two cycles of fludarabine, another patient, seropositive for hepatitis C, withdrew because of persistently elevated LFTs following six cycles of fludarabine, the third patient withdrew because of painful splenomegaly following three cycles of fludarabine, and the fourth patient refused further treatment on protocol to seek 'alternative therapy' after receiving three cycles of fludarabine. No patient left the trial during consolidation with high-dose cyclophosphamide. Because these four patients withdrew from the trial early they were assessed as failures and ultimately only 21 (84%) Table 2 . After completing fludarabine therapy, two patients achieved a CR, two a nodular PR, and 15 patients achieved a PR. In the 15 patients with a PR after fludarabine, consolidation with high-dose cyclophosphamide improved the response in eight patients; four to a nodular PR, and four to a CR. Seven patients remained in PR despite consolidation with high-dose cyclophosphamide. The two patients with nodular PR after fludarabine both improved their response to CR with high-dose cyclophosphamide consolidation. Overall, of the 19 patients to achieve at least a PR to fludarabine 10 (53%) improved the quality of their response following consolidation with high-dose cyclophosphamide.
Flow cytometry was used to detect clonal excess and lymphocytes which dual stained for CD5 and CD19 (or CD20), in order to establish a diagnosis of CLL and to serially follow patient samples for residual disease. Table 2 outlines the results of immunophenotypic analysis after six cycles of fludarabine and again after completion of therapy. Only two patients (8%) achieved a flow cytometric CR (no flow cytometric evidence for residual CLL) after six cycles of fludarabine, this improved to nine patients (36%) having no flow cytometric evidence of disease in the blood or bone marrow after consolidation with high-dose cyclophosphamide.
Fourteen (74%) of the 19 responding patients had 'clonotypic' oligonucleotides constructed. Three of these patients were not evaluable by PCR. In two patients the predicted size band could not be amplified from pre-treatment samples and in one patient the constructed primers had too low a sensitivity for the target sequence. The remaining 11 patients had sequential blood and bone marrow samples tested for residual disease by 'clonotypic' PCR. This technique has the ability to detect one malignant cell in a background of 100 000 polyclonal cells. 17 In eight of these patients semi-quantitative PCR was employed. At the end of therapy seven patients who achieved a PR (three patients) or a nodular PR (four patients) were tested by PCR and all of these patients had evidence of residual disease by this test. Four patients in CR after completing all treatment were also tested and in three of the patients minimal residual disease could not be detected by clonotypic PCR (molecular CR). This result was particularly striking in that all three patients who tested negative by PCR after all therapy had morphologic evidence of residual disease after six cycles of fludarabine (two patients achieved a PR and one Only two of these patients received consolidation with cyclophosphamide as the other four withdrew from study during fludarabine therapy. b All patients testing PCR negative at the end of therapy had morphologic evidence of residual disease after fludarabine.
patient a nodular PR). In addition to the three patients who converted to a negative PCR following consolidation with high-dose cyclophosphamide three patients had evidence of disease reduction (two to four logs in magnitude) as assessed by semi-quantitative PCR following consolidation therapy. Further follow-up of these three patients with molecular CRs revealed response durations of 10, 20 and 48 months. One of these patients died at 37 months of infectious complications. The other two patients (both of whom were treated for high risk disease) remain alive and well (currently with stage 0 disease) at 51+ and 56+ months. Neither of these patients have yet required further chemotherapy for their disease. Median duration of response was similar for patients achieving a PR or nodular PR at 12 months and 16 months, respectively (Figure 1 ). Patients achieving a CR had a significantly longer duration of response with a median of 33 months (P = 0.011). Median time to first non-protocol chemotherapy (time to treatment failure) also correlated with quality of response at 20 months for partial responders, 50 months for patients achieving a nodular PR, and not reached (Ͼ58 months) for those with CR. Figure 2 illustrates overall survival for patients receiving at least one dose of cyclophosphamide (70% at 6 years) and Figure 3 compares survival for the patients achieving a CR or nodular response to the other patients. The high quality responses are associated with significantly improved survival (91% vs 42% at 6 years; P = 0.012) when compared by the log-rank method.
At the end of therapy patients in flow cytometric CR compared with patients who had disease detectable by flow cytometry had a superior response duration (29 vs 13 months), time to treatment failure (76 vs 29 months), and survival (88% vs 57% at 6 years) suggesting the clinical utility of measuring minimal residual disease by this method and the clinical benefit of achieving high quality responses.
Toxicity
No treatment-related deaths occurred, and no patients were removed from study due to unacceptable toxicity. Toxicity encountered during six cycles of fludarabine was consistent with prior experience (Table 3) . Five patients (24%) required hospitalization during therapy with fludarabine. These were primarily for infectious complications, including severe dermatomal Herpes zoster, catheter-related bacteremia, and febrile neutropenia. Seven patients (33%) developed neutropenia while receiving fludarabine and received G-CSF 5 g/kg/day subcutaneously for 3-10 days with subsequent flu- darabine cycles. Two patients (9%) were transfused red cells while receiving fludarabine. Three patients (14%) developed evidence of hemolytic anemia while receiving fludarabine (one each after cycle three, five and six). Consolidation with high-dose cyclophosphamide was myelosuppressive despite G-CSF administration. As expected, all patients developed transient grade 4 neutropenia with ANC Ͻ500/l after each cycle of high-dose cyclophosphamide at 3 g/m 2 . Nine patients (43%) required hospitalization during consolidation therapy with high-dose cyclophosphamide for predominantly febrile neutropenia although no definite infections were documented. G-CSF therapy accelerated recovery of neutrophil counts so that the median hospital stay was only 4 days (range 2-16). Eight patients (36%) received red cell transfusions, and four patients (18%) received platelet transfusions. Microscopic hematuria occurred in two patients and these individuals received mesna during subsequent cycles of high-dose cyclophosphamide. Other complications included a patient who developed a febrile illness complicated by mild Guillain-Barre syndrome 2 weeks after completing therapy. Clinically, this patient had transient motor weakness which subsequently completely resolved. This patient achieved a CR at final evaluation.
Discussion
The results of a large intergroup trial which randomized patients to receive either fludarabine, chlorambucil, or combination chemotherapy with fludarabine and chlorambucil have been reported in abstract form. 19 This study demonstrated an improved incidence of response and progression-free survival for the patients randomized to fludarabine. These results confirmed the activity seen in phase II trials and demonstrated that fludarabine is the single most active agent for patients with CLL. Despite this finding, only a minority of patients achieved a complete response when treated with fludarabine alone. In order to improve the efficacy of fludarabine, several investigators have combined this purine analog with other agents active in CLL. In previously treated patients, excess toxicity without clear-cut improvement in anti-leukemic activity led investigators to abandon combining fludarabine with prednisone 3 or chlorambucil. 5, 6 Similar results were seen for previously untreated patients, where excess toxicity led to the premature closure of the chlorambucil + fludarabine arm in the above described intergroup randomized trial. 20 O'Brien et al 21 reported on the concomitant administration of fludarabine plus cyclophosphamide. This regimen was found to have significant activity, but infectious complications required substantial compromise of the dose intensity of the individual agents with fludarabine administered at 70% of the dose given in our trial and cyclophosphamide given at 30% of the dose administered in our trial. Despite these dose reductions, substantial infectious toxicity included a 7% incidence of sepsis and a 23% incidence of pneumonia. In contrast, the present study used a sequential strategy, which allowed for administration of full-dose fludarabine followed by dose-intense consolidation with cyclophosphamide. This sequential approach achieved a substantial improvement in the quality of response seen with fludarabine alone and did so with acceptable toxicity.
Until recently, the interpretation of clinical trials for patients with CLL has been confounded by the lack of conventions for rigorous response assessment. In 1996, the NCI convened working group published revised response criteria and Leukemia emphasized the need for bone marrow biopsy specimens to distinguish those patients with residual nodules from patients achieving a CR. 22 Our results confirm those of Robertson et al 23 who found that patients with residual nodules had a shorter duration of response than those with a normal bone marrow histology.
The overall incidence of response of patients in this study after six cycles of fludarabine was 76% with CR in 8%, nodular PR in 8%, and PR in 60%. There are only limited published data from prior studies of single agent fludarabine in previously untreated patients. These trials reported similar incidence of response at 89%, 9 70%, 19 and 71%. 24 Two of the six patients to fail fludarabine continued protocol therapy and received consolidation with high-dose cyclophosphamide. Neither of these patients responded to cyclophosphamide treatment. Rather, the benefit seen with high-dose cyclophosphamide consolidation was manifested as an improved quality of response in patients achieving at least a PR to fludarabine. In the three reported trials of single agent fludarabine in previously untreated patients, there is a higher incidence of complete response with fludarabine alone than the 8% achieved in this trial prior to cyclophosphamide consolidation. Two of these studies, 19, 24 however, only report data for CR and PR. Nodular responses are not separately reported and therefore the incidence of CR in these reports may include patients with nodular responses. Our result of CR plus nodular responses in 16% of patients may be consistent with the 21% incidence of CR in the European trial 24 and 27% CRs reported by Rai et al. 19 These results contrast with the report by Keating et al, 9 in which 33% of patients achieved a CR to single agent fludarabine. The reported differences in the frequency of CR may be due to several reasons, including patient selection, criteria for response, and fludarabine dose delivered.
In the current study, we included only those patients in need of immediate treatment for their CLL, with either high risk disease (and worsening anemia or thrombocytopenia) or with 'active' intermediate risk disease, defined as symptomatic disease or a rapid increase in disease burden. Some of the previous trials may have included patients who would not have been treated on this protocol, and therefore the patient cohorts may not be precisely comparable. Additionally, patients on the current study had a relatively high ␤-2 microglobulin suggesting that we treated a group with a particularly poor prognosis. There are obvious limitations in comparing one phase II trial to another. In this trial, however, each patient acts as their own 'control' as we assessed response after fludarabine therapy and compared this to the response achieved after all therapy.
This study demonstrates that consolidation with high-dose cyclophosphamide can improve the quality of response achieved with fludarabine in previously untreated patients with intermediate or high risk CLL. There was a substantial increase in the highest quality responses including CRs (32% vs 8%), nodular responses (16% vs 8%), flow cytometric CRs (36% vs 8%), and molecular (PCR) CRs (12% vs 0%). The fact that patients achieving these high quality responses have a significantly prolonged survival compared with other patients may imply a clinical benefit of this sequential approach for patients with previously untreated CLL.
Although there is no benefit at present in treating early stage CLL 25 it is possible that curative therapies will be feasible in the future. A very high quality response (disease not detectable by 'clonotypic' PCR) is an initial step toward treatment strategies designed to eliminate minimal residual disease. Based on the encouraging results of this sequential treatment strategy in conjunction with our ability to study patient samples with extremely sensitive measures of residual disease we have recently initiated a new three-stage treatment program. On this new protocol we treat patients with six cycles of fludarabine as induction therapy followed by high-dose cyclophosphamide for three cycles which is then followed by a second consolidation with rituximab for four cycles. We hypothesize that this new treatment regimen, using sequential non-crossresistant agents, will further improve the quality of response in patients with CLL.
